News

The 2019 Strategic Plan of the Infectious Diseases Society of America lays the groundwork for understanding prescribing practices.

A clinician offers his perspective on how the virus is behaving and the role that vaccines and therapies will play.

Moderna was endorsed to begin phase 3 clinical trials for mRNA-1345, what could be the first respiratory syncytial virus (RSV) vaccine.

COVID-19 patients’ ZIP codes influenced how sick they were upon hospitalization, and how much care they needed after admittance.

A review of treatment modalities for this patient population.

Latest update of the bill introduced in the House November, but no word on a potential vote yet.

Shorter durations of antibiotic therapy demonstrate similar efficacy and may improve safety compared with longer courses for certain infections.

Study highlights elevated levels of antibody response in those with history of COVID-19.

COVID-19 mRNA vaccine effectiveness wanes even faster during Omicron than during Delta variant predominance, but a booster dose still provides lasting defense against COVID-19 hospitalization and death.

A study of patients at high risk of severe COVID-19 disease progression found ivermectin was no more effective than standard care at preventing adverse outcomes.

Regular symptom screening revealed completely asymptomatic COVID-19 infection is highly unlikely among unvaccinated people.

As the number of COVID-19 cases continues to rise, oral treatment options for at-home use are in demand to provide early intervention and reduce the progression to severe disease, hospitalization, and death.

The varicella zoster (chickenpox) virus has been essentially eradicated thanks to the vaccine developed by Japanese virologist Dr. Michiaki Takahashi, who would have been 94 years old today.

Investigators looked at myocardial infarction risks over several years within 2 health care systems examining both people with HIV (PWH) and people without HIV (PWoH).

Investigators examined the efficacy and safety of carbapenems vs select novel antibiotics for treatment of cUTI.

The investigational therapy has demonstrated promising results utilizing subcutaneous injections every 6 months.

Hispanic/Latino people face disproportionately high HIV incidence, but one CROI 2022 study found those not born in the US are more likely to have stage 3 HIV (AIDS) diagnoses.

Due to policies rolling out HIV pre-exposure prophylaxis (PrEP) and commencing antiretroviral therapy at diagnosis, the UK is on track to eliminate new HIV infections among gay and bisexual men in approximately 25 years.

For people living with HIV (PLWH) an accelerated aging process may affect the severity of their disease.

This nitroimidazole antibiotic is shown to be efficacious for this condition.

After presenting at CROI 2022, Dr. Jessica Justman discusses her community-level survey findings: COVID-19 infections do not vary by age.

A study found 5% of German test-site visitors had a sexually transmitted infection. STI rates, including HIV incidence, were highest among men who have sex with men.

This patient is the first mixed race woman to experience HIV-1 remission, and potentially opens up the door to others being treated with a novel treatment.

Black patients enrolled in an LA Medical Care Coordination program were less likely to achieve viral suppression than HIV-positive people of other races.

The idea of a future with COVID-19 is settling in, and building strategies that improve quality of life as we live with this viral disease are paramount.

Though HIV diagnoses have declined overall, new infections still disproportionately occur in certain racial, ethic, gender, and geographic populations.

Investigators found a couple of different factors for this phenomenon.

In a global cohort, more than 1 in 3 people living with HIV reported functional impairments. Functional impairment was more common among HIV-positive people who were older, Black, or female.

Data shown in the Pinetree clinical trial and being presented with 2 posters at CROI demonstrate both benefits and safety in preventing progression to more severe disease.